Exposure of medical students to pharmaceutical marketing in primary care settings: frequent and influential

  • Ozlem SarikayaEmail author
  • Murat Civaner
  • Kevser Vatansever


It is known that interaction between pharmaceutical companies and medical professionals may lead to corruption of professional values, irrational use of medicine, and negative effects on the patient–physician relationship. Medical students frequently interact with pharmaceutical company representatives and increasingly accept their gifts. Considering the move toward early clinical encounters and community-based education, which expose students early to pharmaceutical representatives, the influence of those gifts is becoming a matter of concern. This study examines the frequency and influence of student exposure to drug marketing in primary care settings, as well as student perceptions of physician–pharmaceutical company relationships. This was a two-phase study consisting of qualitative research followed by a cross-sectional survey. Clinical experience logbooks of 280 second-year students in one school were analysed, and the themes that emerged were used to develop a survey that was administered to 308 third-year students from two medical schools. Survey results showed a 91.2% exposure to any type of marketing, and 56.8% of students were exposed to all classes of marketing methods studied. Deliberate targeting of students by pharmaceutical representatives, in particular, was correlated with being less sensitive to the negative effects of and having positive opinions about interactions with pharmaceutical companies. The vast majority of students are exposed to drug marketing in primary care settings, and may become more vulnerable to that strategy. Considering that medical students are vulnerable and are targeted deliberately by pharmaceutical companies, interventions aimed at developing skills in the rational use of medicines and in strategies for coping with drug marketing should be devised.


Drug industry relationships Conflict of interest Pharmaceutical representatives Marketing methods Primary health care settings 



None of the authors has any conflict of interest with any PC. This study was not supported financially. We thank the students, who sincerely shared and allowed us to use their thoughts.


  1. Akici, A., et al. (2004). Comparison of rational pharmacotherapy decision-making competence of general practitioners with intern doctors. European Journal of Clinical Pharmacology, 60, 75–82. doi: 10.1007/s00228-004-0751-2.CrossRefGoogle Scholar
  2. Barfett, J., et al. (2004). Pharmaceutical marketing to medical students: The student perspective. McGill Journal of Medicine, 8, 21–27.Google Scholar
  3. Bellin, M., et al. (2004). Medical students’ exposure to pharmaceutical industry marketing: A survey at one US medical school. Academic Medicine, 79, 1041–1045. doi: 10.1097/00001888-200411000-00005.CrossRefGoogle Scholar
  4. Civaner, M. (2006). The marketing methods of pharmaceutical companies in Turkey and ethical analysis of physicians’ arguments on this subject (Unpublished PhD thesis). Dissertation, Ankara University.Google Scholar
  5. Cohen, J. J. (2006). Professionalism in medical education, an American perspective: From evidence to accountability. Medical Education, 40, 607–617. doi: 10.1111/j.1365-2929.2006.02512.x.CrossRefGoogle Scholar
  6. Daniel, E. E., & Leedham, L. (1966). Effect on student attitudes of a program of critical evaluation of claims for drugs. Journal of Medical Education, 41, 49–60.Google Scholar
  7. de Vries, T. P., et al. (1995). Impact of a short course in pharmacotherapy for undergraduate medical students: An international randomised controlled study. Lancet, 346, 1454–1457. doi: 10.1016/S0140-6736(95)92472-8.CrossRefGoogle Scholar
  8. Dornan, T., & Bundy, C. (2004). What can experience add to early medical education? Consensus survey. British Medical Journal (Clinical Research Ed.), 329, 834. doi: 10.1136/bmj.329.7470.834.CrossRefGoogle Scholar
  9. Garb, S. (1960). Teaching medical students to evaluate drug advertising. Journal of Medical Education, 35, 729–739.Google Scholar
  10. Goodman, R. L. (2007). Medical education and the pharmaceutical industry. Perspectives in Biology and Medicine, 50, 32–39. doi: 10.1353/pbm.2007.0005.CrossRefGoogle Scholar
  11. Hafferty, F. W. (1998). Beyond curriculum reform: Confronting medicine’s hidden curriculum. Academic Medicine, 73, 403–407. doi: 10.1097/00001888-199804000-00013.CrossRefGoogle Scholar
  12. Hodges, B. (1995). Interactions with the pharmaceutical industry: Experiences and attitudes of psychiatry residents, interns and clerks. Canadian Medical Association Journal, 153, 553–559.Google Scholar
  13. Hyman, P. L., et al. (2007). Attitudes of preclinical and clinical medical students toward interactions with the pharmaceutical industry. Academic Medicine, 82, 94–99. doi: 10.1097/01.ACM.0000249907.88740.ef.CrossRefGoogle Scholar
  14. Kumar, C. J., et al. (2006). Awareness and attitudes about disease mongering among medical and pharmaceutical students. PLoS Medicine, 3, e213. doi: 10.1371/journal.pmed.0030213.CrossRefGoogle Scholar
  15. Lexchin, J., et al. (1993). Interactions between physicians and the pharmaceutical industry: What does the literature say? Canadian Medical Association Journal, 149, 1401–1407.Google Scholar
  16. Littlewood, S., et al. (2005). Early practical experience and the social responsiveness of clinical education: systematic review. British Medical Journal (Clinical Research Ed.), 331, 387–391. doi: 10.1136/bmj.331.7513.387.CrossRefGoogle Scholar
  17. Miettola, J., et al. (2005). Doctor–patient interaction in Finnish primary health care as perceived by first year medical students. BMC Medical Education, 5, 34. doi: 10.1186/1472-6920-5-34.CrossRefGoogle Scholar
  18. Monaghan, M. S., et al. (2003). Student understanding of the relationship between the health professions and the pharmaceutical industry. Teaching and Learning in Medicine, 15, 14–20. doi: 10.1207/S15328015TLM1501_04.CrossRefGoogle Scholar
  19. Norris, P., et al. (2005). Drug promotion. What we know, what we have yet to learn. Geneva: WHO.Google Scholar
  20. Palmisano, P., & Edelstein, J. (1980). Teaching drug promotion abuses to health profession students. Journal of Medical Education, 55, 453–455.Google Scholar
  21. Prideaux, D., & Worley, P. (2007). Symbiosis: A new model for clinical education. The Clinical Teacher, 4, 209–212. doi: 10.1111/j.1743-498X.2007.00188.x.CrossRefGoogle Scholar
  22. Reddy, S. T., et al. (2007). Third-year medical students’ participation in and perceptions of unprofessional behaviors. Academic Medicine, 82, S35–S39.CrossRefGoogle Scholar
  23. Reuler, J. B., & Nardone, D. A. (1994). Role modeling in medical education. The Western Journal of Medicine, 160, 335–337.Google Scholar
  24. Rogers, W. A., et al. (2004). The ethics of pharmaceutical industry relationships with medical students. The Medical Journal of Australia, 180, 411–414.Google Scholar
  25. Sandberg, W. S., et al. (1997). The effect of educational gifts from pharmaceutical firms on medical students’ recall of company names or products. Academic Medicine, 72, 916–918. doi: 10.1097/00001888-199710000-00018.CrossRefGoogle Scholar
  26. Shear, N., et al. (1996). Examining the physician–detailer interaction. The Canadian Journal of Clinical Pharmacology, 3, 175–179.Google Scholar
  27. Sierles, F. S., et al. (2005). Medical students’ exposure to and attitudes about drug company interactions: A national survey. Journal of the American Medical Association, 294, 1034–1042. doi: 10.1001/jama.294.9.1034.CrossRefGoogle Scholar
  28. Suryawati, S., & Santoso, B. (1997). Drug advertisements: A critical lesson for Indonesian students. Essential Drugs Monitor, 23, 23.Google Scholar
  29. Vainiomaki, M., et al. (2004). A national survey on the effect of pharmaceutical promotion on medical students. Medical Teacher, 26, 630–634. doi: 10.1080/01421590400004890.CrossRefGoogle Scholar
  30. Vinson, D. C., et al. (1993). Medical students’ attitudes toward pharmaceutical marketing: Possibilities for change. Family Medicine, 25, 31–33.Google Scholar
  31. Wazana, A. (2000). Physicians and the pharmaceutical industry: Is a gift ever just a gift? Journal of the American Medical Association, 283, 373–380. doi: 10.1001/jama.283.3.373.CrossRefGoogle Scholar
  32. Westfall, J. M. (2000). Physicians, pharmaceutical representatives, and patients: Who really benefits? The Journal of Family Practice, 49, 817–819.Google Scholar
  33. Wilkes, M. S., & Hoffman, J. R. (2001). An innovative approach to educating medical students about pharmaceutical promotion. Academic Medicine, 76, 1271–1277. doi: 10.1097/00001888-200112000-00026.CrossRefGoogle Scholar
  34. Wofford, J. L., & Ohl, C. A. (2005). Teaching appropriate interactions with pharmaceutical company representatives: The impact of an innovative workshop on student attitudes. BMC Medical Education, 5, 5. doi: 10.1186/1472-6920-5-5.CrossRefGoogle Scholar
  35. Wright, S., et al. (1997). The impact of role models on medical students. Journal of General Internal Medicine, 12, 53–56. doi: 10.1007/s11606-006-0007-1.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Ozlem Sarikaya
    • 1
    Email author
  • Murat Civaner
    • 2
  • Kevser Vatansever
    • 3
  1. 1.Department of Medical EducationMarmara University School of MedicineUskudar, IstanbulTurkey
  2. 2.Department of DeontologyUludag University School of MedicineBursaTurkey
  3. 3.Department of Medical EducationEge University School of MedicineIzmirTurkey

Personalised recommendations